Multiple clinical trials on BRD4 inhibitors and NR3C1‐specific inhibitors have been carried out (such as NCT04309968: SYHA1801 in advanced solid tumors, NCT03205176: AZD5153 in refractory solid tumors, and NCT03776812: relacorilant in recurrent platinum‐resistant ovarian, fallopian tube, or primary peritoneal cancer), with drug efficacy results eagerly awaited. This evidence concerns the gene BRD4 and peritoneum cancer.